martes, 5 de agosto de 2014

National Guideline Clearinghouse | Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.

full-text ►

National Guideline Clearinghouse | Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.



National Institute for Health and Care Excellence (NICE)

National Guideline Clearinghouse (NGC)

Guideline Title
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer.
Bibliographic Source(s)
National Institute for Health and Care Excellence. Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. London (UK): National Institute for Health and Care Excellence; 2014 Apr. 40 p. (Technology appraisal guidance; no. 310). 
Guideline Status
This is the current release of the guideline.
This guideline meets NGC's 2013 (revised) inclusion criteria.

No hay comentarios:

Publicar un comentario